Fulcrum Therapeutics saw the highest growth of 1.99% in patent filings in June and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.49% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Fulcrum Therapeutics’s patent filings and grants. Buy the databook here.
Fulcrum Therapeutics has been focused on protecting inventions in United States(US) with two publications in Q2 2024
The United States(US) Patent Office dominates the patent filings with nearly 50% of filings. The United States(US), European Patent Office(EPO), and South Korea(KR) patent Office are among the top ten patent offices where Fulcrum Therapeutics is filings its patents..
Roche and Johnson & Johnson could be the strongest competitors for Fulcrum Therapeutics
Patents related to rare diseases lead Fulcrum Therapeutics's portfolio
Fulcrum Therapeutics has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Leukemia related patents lead Fulcrum Therapeutics portfolio followed by venous thromboembolism, and leukopenia
Fulcrum Therapeutics has highest number of patents in leukemia followed by venous thromboembolism, leukopenia, paraproteinemias, and amyloidosis.
For comprehensive analysis of Fulcrum Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.